Efficacy and safety analysis of disitamab vedotin combined with immunotherapy as neoadjuvant treatment to promote conversion to bladder preservation in bladder cancer: A retrospective comparative study with the GC combined with immunotherapy regimen

Urologic Oncology: Seminars and Original Investigations · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles